Patogeneticheskiy podkhod k primeneniyu al'fa-lipoevoy kisloty v lechenii erektil'noy disfunktsii u patsientov s sakharnym diabetom


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to the assessment of the effectiveness of the alpha-lipoic acid at a dose of 600 mg per day in patients with diabetes mellitus (DM) type 2, erectile dysfunction (ED), disorders of libido, and other clinically significant symptoms of androgen deficiency. The study included 86 men with erectile dysfunction. The patient’s mean age was 51 year. Study group comprised 52 patients, control group included 34 patients. Evaluation of the effectiveness of the treatment was performed 12 weeks after administration of the drug. For the evaluation of the effectiveness of the therapy, validated questionnaires were used: the International Index of Erectile Function 5 (IIEF-5), and the Aging Male Simptoms (AMS) by Heinemann. The results of the study allow to recommend the alpha-lipoic acid as a pathogenic agent for the treatment of erectile dysfunction in patients with diabetes mellitus.

Full Text

Restricted Access

References

  1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993; 270(1): 83-90.
  2. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151(1): 54-61.
  3. Ефремов Е.А. Эректильная дисфункция как полиэтиологический синдром. Автореф. дисс.. докт. мед. наук. М., 2011.
  4. Maiorino M.I., Bellastella G., Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes. 2014; 7: 95-105.
  5. International Diabetes Federation. IDF Diabetes Atlas. 5th edition. Brussels, Belgium: International Diabetes Federation; 2012.
  6. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5): 1047-53.
  7. Mitkov M.D., Aleksandrova I.Y., Orbetzova M.M. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv). 2013; 55(1): 55-63.
  8. Ефремов Е.А. Эректильная дисфункция как полиэтиологический синдром. Дисс.. докт. мед. наук. М., 2011. 448 с.
  9. Burnett A.L., Lowenstein C.J., Bredt D.S., et al. Nitric oxide: a physiologic mediator of penile erection. Science. 1992; 257(5068): 401-03.
  10. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327(6122): 524-26.
  11. Rendell M.S., Rajfer J., Wicker P.A., Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999; 281(5): 421-26.
  12. Zalba G., Beaumont J., San Jose G., et al. Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J. Physiol. Biochem. 2000; 56(1): 57-64.
  13. Beckman J.S., Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 1996; 271(5 Pt 1): 1424-37.
  14. Ворслов Л.О., Калинченко С.Ю., Гадзиева И.В. «Квартет здоровья» против «смертельного квартета». Ч. 1: метаболическая невропатия - легко диагностировать, трудно лечить. Эффективная фармакотерапия. Урология и нефрология. 2013; 1: 38-47.
  15. Храмилин В.Н., Демидова И.Ю., Рагозин А.К. Перспективы клинического применения альфа-липоевой кислоты. Consilium Medicum. 2001; 3(11).
  16. Jones R.W., Rees R.W., Minhas S., et al. Oxygen free radicals and the penis. Expert Opin. Pharmacother. 2002; 3(7): 889-97.
  17. Khan M.A., Thompson C.S., Mumtaz F.H., et al. The effect of nitric oxide and peroxynitrite on rabbit cavernosal smooth muscle relaxation. World J. Urol. 2001; 19(3): 220-24.
  18. Jeremy J.Y., Angelini G.D., Khan M., et al. Platelets, oxidant stress and erectile dysfunction: an hypothesis. Cardiovasc. Res. 2000; 46(1): 50-4.
  19. Hermann R., Niebch G. Human pharmacokinetics of a-lipoic acid. In Lipoic acid in health and disease Fuchs J., Packer L., Zimmer G. (eds.). N-Y: Marcel Dekker Inc, 1997. P. 337-60.
  20. Бондарь И.А., Королева Е.А. Альфа-липоевая кислота (Эспа-липон) - доказательства эффективности лечения диабетической нейропатии. Эффективная фармакология. Эндокринология. 2013; 2(22).
  21. Keegan A., Cotter M.A., Cameron N.E. Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia. 1999; 42(3): 343-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies